flopristin

Flopristin is a **synthetic streptogramin A antibiotic** and a member of the streptogramin class, typically formulated and investigated as part of the combination drug linopristin/flopristin (NXL103, XRP 2868)[1][3][5][7]. Streptogramins inhibit bacterial protein synthesis by binding to the 50S subunit of bacterial ribosomes, resulting in a bactericidal effect against susceptible organisms. Flopristin itself has potent in vitro activity, primarily against gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus species, Enterococcus, and other clinically relevant Gram-positive bacteria[1][3][4][7]. Its use as a single agent is not described in clinical development, but patents suggest it may be considered for various infections such as skin and soft tissue infections, pneumonia, bone/joint infections, sexually transmitted infections, genitourinary tract infections, and as adjunctive or monotherapy in resistant bacterial infections[4].